A cross-talk exists between KRAS mutation and MTOR hyperactivated mouse model in hepatocellular carcinoma (HCC), which acts through a paternally expressed-3 (PEG3)-mediated-signaling pathway [80]. This evidence concerns the gene MTOR and hepatocellular carcinoma.